Iress reports 9% decline in NPAT but OneVue a key focus
Iress has reported a 9% decline in net profit after tax (NPAT) but the OneVue integration is a key focus for 2021 as it looks to grow funds registry by value and funds.
Releasing its 2020 full-year results to the Australian Securities Exchange (ASX), the firm said reported revenue increased by 8% but reported NPAT was down 9%.
The full year 2020 dividend was 46.0 cents per share, franked to 38% on an average weighted basis.
The firm also appointed Roger Sharp as its new chair following the retirement of current chair Tony D’Aloisio after eight years on the board.
Integration of OneVue, which it acquired in November, was underway and this would enable the firm to provide investment advice from Xplan. The integration was one of the firm’s key focuses for 2021 to grow funds registry by value and provide investment infrastructure-as-a-service (IaaS).
“Our Australian business continues to deliver growth with consistently high returns. We made good progress executing our growth strategies including turning QuantHouse to profitability on a monthly basis and in providing Australian super funds with a highly efficient, outsourced administration solution.”
However, the firm’s progress in the UK was delayed with revenue excluding 2020 acquisitions down 3% due to the COVID-19 pandemic which impacted the timing of key client projects.
AUTHOR
Laura Dew
Recommended for you
Compared to four years ago when the divide between boutique and large licensees were largely equal, adviser movements have seen this trend shift in light of new licensees commencing.
As ongoing market uncertainty sees advisers look beyond traditional equity exposure, Fidante has found adviser interest in small caps and emerging markets for portfolio returns has almost doubled since April.
CoreData has shared the top areas of demand for cryptocurrency advice but finds investors are seeking advisers who actively invest in the asset themselves.
With regulators ‘raising the bar’ on retirement planning, Lonsec Research and Ratings has urged advisers to place greater focus on sequencing and longevity risk as they navigate clients through the shifting landscape.
